Empagliflozin
Abdominal Obesity-Metabolic Syndrome
Explore 42 assets in Abdominal Obesity-Metabolic Syndrome →Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Abdelrahman Mahmoud
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
64Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07322237CT.gov DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis | — | Recruiting | — | — | — |
NCT07472920CT.gov Empagliflozin Adjunctive Therapy in Bipolar Depression | — | Not Yet Recruiting | — | — | — |
NCT07336797CT.gov Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy | — | Recruiting | — | — | — |
NCT07065357CT.gov Treating the Metabolic Syndrome With a Sodium-glucose Cotransporter-2 Inhibitor | — | Enrolling By Invitation | — | — | — |
NCT06410352CT.gov Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome | — | Recruiting | — | — | — |
NCT05972564CT.gov The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function | — | Recruiting | — | — | — |
NCT05905965CT.gov Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment | — | Recruiting | — | — | — |
NCT04221152CT.gov A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 ) | — | Unknown | — | — | — |
NCT04131582CT.gov Effect of Empagliflozin + Linagliptin + Metformin + Lifestyle in Patients With Prediabetes | — | Unknown | — | — | — |
NCT04018365CT.gov A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance | — | Unknown | — | — | — |
Show 1 more trialShow fewer
NCT03912909CT.gov Effects of Sodium-glucose Co-transporter-2( SGLT-2 ) Inhibition on Sympathetic Nervous System Activity in Humans | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Abdominal Obesity-Metabolic Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Empagliflozin (this asset) | Abdelrahman Mahmoud | Approved | BB · 68 |
| Topiramate | All India Institute of Medical Sciences, Bhubaneswar | P4 | BBB |
| Atorvastatin | Seoul National University Hospital | P4 | BBB |
| Pioglitazone | Philip Kern | P4 | BBB |
| Simvastatin | Jaime Daniel Mondragon | P4 | BBB |
| Rosuvastatin | Hamdard University | P4 | BBB |
| Olmesartan Medoxomil | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | P4 | BBB |
| Ezetimibe | Samsung Medical Center | P4 | BB |
| Amlodipine | Italo Biaggioni | P4 | BB |
+42 more in the Abdominal Obesity-Metabolic Syndrome cohort
Other indications for Empagliflozin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prediabetes Syndrome | — | P4 | BBB · 74 |
| Metabolic Dysfunction-Associated Steatotic Liver Disease | — | P4 | BBB · 73 |
| Type 2 Diabetes Mellitus | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Empagliflozin in Abdominal Obesity-Metabolic Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/empagliflozin-abdominal-obesity-metabolic-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →